Adam Waldman (Affiliate)
Imaging Biomarkers in Adult Glioma
Research in a Nutshell
The overall theme of my research is development and validation of quantitative and molecular imaging biomarkers which reflect key features of genetics and metabolism in human glioma, for clinical stratification, therapeutic planning and drug development:
Experimental phase MRI and PET imaging studies of intermediary metabolism, validated against tissue metabolic markers from defined tumour regions; for more reliable tumour characterisation, and identification of potential therapeutic targets.
Translational multi-centre platform studies of early therapeutic response in GBM using quantitative diffusion imaging for improved endpoints in clinical trials and clinical decision-making.
Quantitative MRI for treatment stratification and planning in adult supratentorial low grade glioma.
Development of PET-MRI methodology and co-analysis for improved glioma characterization.
Integration of quantitative MRI and PET into surgical neuro-navigation systems, for improved targeting for biopsy and surgical resection.
People |
|
| Adam Waldman | Principal Investigator and Professor of Neuroradiology |
| Gerard Thompson | Senior Lecturer in Neuroradiology |
| Antoine Vallatos | Research Associate in Preclinical and Clinical Brain Imaging |
| Matt Grech-Sollars | Post Doctoral RA (based at Imperial College, London) |
| Shah Islam | Clinical Research Fellow (based at Imperial College, London) |
| Melanie Morrison | Post Doctoral RA (based at Imperial College, London) |
Contact
Collaborations
- Dr Steve Pollard, University of Edinburgh
- Professor Anthony Chalmers, University of Glasgow
- Professor Eric Aboagye, Imperial College London
- Professor Catharina Svanborg, University of Lund
Partners and Funders
- The Brain Tumour Charity
- Brain Tumour Research Campaign
Scientific Themes
Imaging of glioma genetics and metabolism, drug distribution and pharmacodynamics; non-invasive markers of progression, invasion and therapeutic response
Technology Expertise
Quantitative and molecular neuroimaging; predominantly quantitative MRI and PET